Kane Biotech Inc.
KNE.V
TSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 11.04% | -75.07% | 70.33% | -9.75% | -56.50% |
| Total Depreciation and Amortization | -11.79% | -21.49% | 0.60% | -26.65% | 33.53% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -215.63% | 117.66% | -164.48% | -50.79% | 95.41% |
| Change in Net Operating Assets | 7.11% | 56.61% | -165.81% | -165.80% | 277.49% |
| Cash from Operations | 3.69% | 9.26% | 27.36% | -156.42% | 23.98% |
| Capital Expenditure | -- | -- | -- | -200.00% | 13.51% |
| Sale of Property, Plant, and Equipment | -100.00% | 581.25% | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | 211.90% |
| Other Investing Activities | -282.93% | 88.58% | -65.44% | 94.24% | -205.46% |
| Cash from Investing | -139.75% | 233.90% | 5.45% | -238.05% | 464.52% |
| Total Debt Issued | -- | -100.00% | -- | -- | -- |
| Total Debt Repaid | 18.22% | 81.10% | 26.83% | -0.26% | -0.26% |
| Issuance of Common Stock | -- | -100.00% | -25.13% | 291.74% | 48.93% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 337.93% | 78.25% | -210.08% | 3.73% | 2.90% |
| Cash from Financing | 2,278.54% | -101.57% | 56.25% | 517.54% | 143.77% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 94.52% | -160.47% | 761.66% | 170.81% | 61.15% |